Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 411

1.

CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.

Bajaj J, Konuma T, Lytle NK, Kwon HY, Ablack JN, Cantor JM, Rizzieri D, Chuah C, Oehler VG, Broome EH, Ball ED, van der Horst EH, Ginsberg MH, Reya T.

Cancer Cell. 2016 Nov 14;30(5):792-805. doi: 10.1016/j.ccell.2016.10.003.

PMID:
27908736
2.

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.

Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M.

J Hematol Oncol. 2016 Dec 1;9(1):134.

3.

Multiplex shRNA Screening of Germ Cell Development by in Vivo Transfection of Mouse Testis.

Ho NR, Usmani AR, Yin Y, Ma L, Conrad DF.

G3 (Bethesda). 2017 Jan 5;7(1):247-255. doi: 10.1534/g3.116.036087.

4.
5.

Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations.

Zhou S, Treloar AE, Lupien M.

Cancer Discov. 2016 Nov;6(11):1215-1229. Review.

PMID:
27807102
6.

Design and characterization of bivalent BET inhibitors.

Tanaka M, Roberts JM, Seo HS, Souza A, Paulk J, Scott TG, DeAngelo SL, Dhe-Paganon S, Bradner JE.

Nat Chem Biol. 2016 Dec;12(12):1089-1096. doi: 10.1038/nchembio.2209.

PMID:
27775715
7.

Erythropoiesis provides a BRD's eye view of BET protein function.

Stonestrom AJ, Hsu SC, Werner MT, Blobel GA.

Drug Discov Today Technol. 2016 Mar;19:23-28. doi: 10.1016/j.ddtec.2016.05.004. Review.

PMID:
27769353
8.

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJ, Iorio F, Pina C, Vassiliou GS, Yusa K.

Cell Rep. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079.

9.

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.

Picaud S, Leonards K, Lambert JP, Dovey O, Wells C, Fedorov O, Monteiro O, Fujisawa T, Wang CY, Lingard H, Tallant C, Nikbin N, Guetzoyan L, Ingham R, Ley SV, Brennan P, Muller S, Samsonova A, Gingras AC, Schwaller J, Vassiliou G, Knapp S, Filippakopoulos P.

Sci Adv. 2016 Oct 12;2(10):e1600760.

10.

Epigenetic polypharmacology: from combination therapy to multitargeted drugs.

de Lera AR, Ganesan A.

Clin Epigenetics. 2016 Oct 12;8:105. Review.

11.

Epigenetics in Cancer: A Hematological Perspective.

Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T.

PLoS Genet. 2016 Oct 10;12(10):e1006193. doi: 10.1371/journal.pgen.1006193. Review.

12.

Synthetic lethality in lung cancer and translation to clinical therapies.

Leung AW, de Silva T, Bally MB, Lockwood WW.

Mol Cancer. 2016 Sep 29;15(1):61. Review.

13.

H3K9me3 demethylase Kdm4d facilitates the formation of pre-initiative complex and regulates DNA replication.

Wu R, Wang Z, Zhang H, Gan H, Zhang Z.

Nucleic Acids Res. 2017 Jan 9;45(1):169-180. doi: 10.1093/nar/gkw848.

14.

BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire.

Najafova Z, Tirado-Magallanes R, Subramaniam M, Hossan T, Schmidt G, Nagarajan S, Baumgart SJ, Mishra VK, Bedi U, Hesse E, Knapp S, Hawse JR, Johnsen SA.

Nucleic Acids Res. 2017 Jan 9;45(1):127-141. doi: 10.1093/nar/gkw826.

15.

Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer.

Gong F, Chiu LY, Miller KM.

PLoS Genet. 2016 Sep 15;12(9):e1006272. doi: 10.1371/journal.pgen.1006272. Review.

16.

Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.

Morgado-Palacin I, Day A, Murga M, Lafarga V, Anton ME, Tubbs A, Chen HT, Ergan A, Anderson R, Bhandoola A, Pike KG, Barlaam B, Cadogan E, Wang X, Pierce AJ, Hubbard C, Armstrong SA, Nussenzweig A, Fernandez-Capetillo O.

Sci Signal. 2016 Sep 13;9(445):ra91. doi: 10.1126/scisignal.aad8243.

PMID:
27625305
17.

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.

Klingbeil O, Lesche R, Gelato KA, Haendler B, Lejeune P.

Cell Death Dis. 2016 Sep 8;7(9):e2365. doi: 10.1038/cddis.2016.271.

18.

Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.

Zhang C, Su ZY, Wang L, Shu L, Yang Y, Guo Y, Pung D, Bountra C, Kong AN.

Biochem Pharmacol. 2016 Oct 1;117:35-45. doi: 10.1016/j.bcp.2016.08.009.

PMID:
27520485
19.

High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML.

Zhao Y, Liu Q, Acharya P, Stengel KR, Sheng Q, Zhou X, Kwak H, Fischer MA, Bradner JE, Strickland SA, Mohan SR, Savona MR, Venters BJ, Zhou MM, Lis JT, Hiebert SW.

Cell Rep. 2016 Aug 16;16(7):2003-16. doi: 10.1016/j.celrep.2016.07.032.

20.

Emerging concepts of epigenetic dysregulation in hematological malignancies.

Ntziachristos P, Abdel-Wahab O, Aifantis I.

Nat Immunol. 2016 Sep;17(9):1016-24. doi: 10.1038/ni.3517. Review.

Items per page

Supplemental Content

Support Center